GVHD

News
Mesoblast stem cell therapy GVHD

Imbruvica granted fourth Breakthrough status

AbbVie’s Imbruvica (ibrutinib) has gained its fourth Breakthrough Therapy Designation from the FDA - this time for the treatment of chronic graft versus host disease (cGVHD) after the failu